BioSight
Companies
UNITED THERAPEUTICS Corp logo

UTHR

NASDAQSILVER SPRING, MD
UNITED THERAPEUTICS Corp

United Therapeutics develops and sells pharmaceutical therapies for rare diseases with unmet medical needs, with a particular focus on pulmonary arterial hypertension (PAH) and related lung conditions. The company markets six approved treatments for PAH in the U.S.—including inhalation, injection, and oral formulations—plus one approved oncology product for high-risk neuroblastoma, while maintaining a pipeline of products in development for PAH, pulmonary fibrosis, and other serious diseases. United Therapeutics also pursues organ manufacturing technologies to expand the availability of transplantable organs.

$571.35+88.51%1Y
UTHR · daily close · illustrative · 0 catalysts marked
$243$338$434$529$625Apr '25Aug '25Dec '25Apr '26
1Y high$592.981Y low$274.70range$318.28(116%)past catalysts

Pipeline3

Inhaled Treprostinil
Phase 3Progressive Pulmonary Fibrosis
Phase 3Interstitial Lung Disease
small-molecule
10 GE Xenokidney
Phase 2ESRD (End-Stage Renal Disease)
Phase 2Kidney Transplantation
Phase 2Xenotransplantation
small-molecule
GGTA1 KO Thymokidney
Phase 2ESRD (End-Stage Renal Disease)
Phase 2Kidney Transplantation
Phase 2Xenotransplantation
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar